Browsing Tag
AIM
64 posts
Serabi Gold (AIM:SRB) shares rise as Q1 production, cash and profit strengthen Brazil mining outlook
Find out how Serabi Gold’s Q1 profit surge, debt-free balance sheet and Coringa ramp-up could reshape AIM investor sentiment.
Is Helium One (HE1.L) finally moving from helium hype to proof?
Helium One has helium, licences and first gas. The harder test is whether HE1.L can secure a partner before dilution fears return.
ImmuPharma at 4p is a P140 licensing bet: What IMM retail investors should know
ImmuPharma targets a P140 licensing deal in 2026 with cash to H2 2028. Here is what IMM retail investors need to weigh before chasing the small-cap biotech.
AVCT entry at 86p is a bet on AVA6103: What Avacta Group investors should know
Avacta Group sets up a binary AVA6103 readout for late H2 2026. Here is what AVCT retail investors need to weigh before the data lands and runway runs.
Avacta FY25 puts AVCT on a clock: £16.9m cash, two Phase 1 reads, one shot
Avacta Group posts FY25 results with two clinical assets in trial, £16.9m cash, and AVA6103 data due in H2 2026 as AVCT trades near 52-week high.
Avacta Group (AIM: AVCT) preCISION data signals tumor selectivity index emerging as the new ADC battleground
Avacta is not just challenging Enhertu. It is rewriting the metric the entire ADC industry will be diligenced on. Tumor selectivity is the new battleground.
Avacta Group (AIM: AVCT) delivers preCISION payload data that challenges Enhertu and Datroway tumor selectivity at Science Day 2026
Avacta is no longer pitching a platform. It is benchmarking preCISION directly against Enhertu and Datroway, and the tumor selectivity numbers matter.
Why Greatland Resources (ASX: GGP) is catching a bid as gold holds above US$4,500 ahead of the June reserve update
Greatland Resources trades at A$13.78 with consensus already at A$13.19. The June reserve update is where the 14.9-million-ounce resource either converts cleanly or stalls.
Mpac Group FY25 results: Can 42% revenue growth offset a weaker order book and rising net debt?
Mpac grew fast, but orders fell. The 2026 test is whether automation demand can outrun customer caution and debt pressure.
Avacta (AIM: AVCT): First patient dosed in FOCUS-01 with three data catalysts lined up across 2026
Avacta (AIM: AVCT) dosed the first FOCUS-01 patient in March 2026. Three catalysts follow: AACR April 21, AVA6000 H1 update, AVA6103 late H2 data. Full retail investor roadmap inside.